About Us
Back to Publications

Moving forward in clinical research with master protocols

With billions of dollars in research and development funding continuing to be invested, COVID-19 has become into a singular focus for the scientific community. However, the collective response from the scientific communities has seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. We argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.
Publications • 2 Min Read

Abstract

With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Read the full article

Share on

Summary

You might be interested

News

Early Treatment with Pegylated Interferon
Lambda for Covid-19

The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.
Read More

News

Resilient clinical trial infrastructure in response to the COVID-19 pandemic: Lessons learned from the TOGETHER randomized platform clinical trial

In 2020, clinical trial researchers developed protocols to evaluate the safety and effectiveness of potential treatments for COVID-19. Despite more than 3,000 trials registered , few have generated findings, with the exception of smaller randomized controlled trials.A clinical trial infrastructure (defined as the human, material, and knowledge networks that form a responsive implementation of productive trial protocols) must be resilient to threats (e.g., COVID-19), and is essential when barriers to sustainable funding are common.
Read More

News

Interferon treatments for SARS-CoV-2: Challenges and opportunities

Interferon (IFN) therapies are used to treat a variety of infections and diseases and could be used to treat SARS-CoV-2. However, optimal use and timing of IFN therapy to treat SARS-CoV-2 is not well documented. We aimed to synthesize available evidence to understand whether interferon therapy should be recommended for treatment compared to a placebo or standard of care in adult patients.While IFN therapy has the potential to be a viable treatment for SARS-CoV-2, especially when combined with antivirals and early administration, the lack of comparable of study outcomes prevents evidence synthesis and uptake.
Read More

Find More Information

Share Link: